Open AccessOutcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)
Author(s) -
Mizumaki Hiroki,
Ishiyama Ken,
Aoki Jun,
Mori Jinichi,
Mizuno Shohei,
Doki Noriko,
Fukuda Takahiro,
Uchida Naoyuki,
Onizuka Masahito,
Tanaka Masatsugu,
Katayama Yuta,
Ozawa Yukiyasu,
Ikegame Kazuhiro,
Takada Satoru,
Kawakita Toshiro,
Aotsuka Nobuyuki,
Atsuta Yoshiko,
Yanada Masamitsu
Publication year - 2023
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.609
Subject(s) - myeloid leukemia , medicine , hematopoietic stem cell transplantation , transplantation , multivariate analysis , stem cell , oncology , haematopoiesis , chromosome 7 (human) , myeloid , monosomy , gastroenterology , chromosome , biology , gene , genetics , karyotype
The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo‐SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (‐7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the ‐7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo‐SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).